Form 4 · Filed Jul 30, 2026, 09:58 PM UTC
NRIX/Nurix Therapeutics, Inc.
van Houte Hans — Chief Financial Officer
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
7 rows| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jul 30, 2026 | M | other | 3,750 | $0 | — | 41,342 |
| Jul 30, 2026 | M | other | 2,858 | $0 | — | 44,200 |
| Jul 30, 2026 | M | other | 3,572 | $0 | — | 47,772 |
| Jul 30, 2026 | S | sell | 2,845 | $23 | $66,524 | 44,927 |
| Jul 30, 2026 | M | other | 3,750 | — | — | 11,250 |
| Jul 30, 2026 | M | other | 2,858 | — | — | 20,009 |
| Jul 30, 2026 | M | other | 3,572 | — | — | 39,303 |
Source: SEC EDGAR raw filing ↗ · Accession 0001817217-26-000010